$4.20
12.68% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US75629V1044
Symbol
RXRX
Sector
Industry

Recursion Pharmaceuticals Stock price

$4.81
-1.78 27.01% 1M
-1.25 20.63% 6M
-1.95 28.85% YTD
-4.12 46.14% 1Y
-2.99 38.33% 3Y
-26.49 84.63% 5Y
-26.49 84.63% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.48 9.07%
ISIN
US75629V1044
Symbol
RXRX
Sector
Industry

Key metrics

Market capitalization $1.93b
Enterprise Value $1.44b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 24.55
P/S ratio (TTM) P/S ratio 32.86
P/B ratio (TTM) P/B ratio 1.84
Revenue growth (TTM) Revenue growth 32.00%
Revenue (TTM) Revenue $58.84m
EBIT (operating result TTM) EBIT $-479.01m
Free Cash Flow (TTM) Free Cash Flow $-372.87m
Cash position $597.40m
EPS (TTM) EPS $-1.66
P/E forward negative
P/S forward 21.74
EV/Sales forward 16.24
Short interest 23.38%
Show more

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Recursion Pharmaceuticals forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
33%
Hold
67%

Financial data from Recursion Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
59 59
32% 32%
100%
- Direct Costs 64 64
4% 4%
108%
-4.69 -4.69
72% 72%
-8%
- Selling and Administrative Expenses 142 142
90% 90%
241%
- Research and Development Expense 296 296
27% 27%
503%
-442 -442
37% 37%
-752%
- Depreciation and Amortization 37 37
0% 0%
62%
EBIT (Operating Income) EBIT -479 -479
33% 33%
-814%
Net Profit -464 -464
41% 41%
-788%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Negative
The Motley Fool
one day ago
Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.
Neutral
GlobeNewsWire
3 days ago
Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor conference: Needham 24th Annual Virtual Healthcare Conference — Monday, April 7, 2025 Webcasts may be found in the events section of the Recursion Investor ...
Negative
The Motley Fool
4 days ago
Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%, respectively, as of 12:55 p.m. ET.
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Chistopher Gibson
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today